Praluent vs Lisinopril: Cost and Access Head-to-Head

What Each Drug Actually Does

Praluent and lisinopril do not compete for the same biological target. Alirocumab is a fully human monoclonal antibody that binds PCSK9, preventing it from degrading LDL receptors on hepatocytes, which drives LDL-C out of the bloodstream [1]. Lisinopril blocks angiotensin-converting enzyme, reducing angiotensin II production, which lowers systemic vascular resistance and blood pressure [2]. A patient with post-ACS hypercholesterolemia and hypertension may need both drugs simultaneously.

Alirocumab Mechanism and Dosing

Praluent is available as 75 mg or 150 mg subcutaneous injections given every two weeks, or 300 mg given every four weeks [3]. If LDL-C response at 75 mg every two weeks is inadequate after eight weeks, the dose is titrated to 150 mg every two weeks. The FDA approved alirocumab in July 2015 for adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease requiring additional LDL-C lowering [3].

Lisinopril Mechanism and Dosing

Lisinopril is dosed orally once daily, typically starting at 5 to 10 mg for hypertension and titrated to a maximum of 40 mg [4]. For heart failure, starting doses of 2.5 to 5 mg are used. Its half-life of approximately 12 hours and lack of active metabolites make it straightforward to dose-adjust. The drug has been off-patent since the 1990s, which is the single biggest reason it costs so little [4].

Efficacy Evidence: Different Trials, Different Questions

These drugs have never been compared in a head-to-head randomized trial, and no such trial is currently registered. The evidence comes from two landmark studies that addressed separate clinical questions.

ODYSSEY OUTCOMES: Alirocumab After ACS

ODYSSEY OUTCOMES enrolled 18,924 patients with recent acute coronary syndrome who were already on high-intensity statin therapy [5]. Participants randomized to alirocumab 75 to 150 mg every two weeks achieved a 15% relative reduction in the primary composite MACE endpoint (coronary heart disease death, non-fatal MI, fatal or non-fatal ischemic stroke, or unstable angina requiring hospitalization) compared with placebo (hazard ratio 0.85, 95% CI 0.78 to 0.93, P<0.001) [5]. Absolute risk reduction was 1.6 percentage points over a median 2.8 years. Among patients with baseline LDL-C at or above 100 mg/dL, the absolute benefit was larger, with a number needed to treat of approximately 39 [5].

The trial also reported a pre-specified all-cause mortality analysis. Alirocumab reduced all-cause death by 15% (HR 0.85, 95% CI 0.73 to 0.98) in the overall population, a signal that reached nominal significance [5]. This mortality signal is what distinguishes ODYSSEY OUTCOMES from earlier PCSK9 inhibitor trials and forms the cornerstone of current high-risk prescribing decisions.

ALLHAT: Lisinopril for Hypertension

The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) randomized 33,357 participants aged 55 and older with hypertension and at least one additional coronary risk factor to chlorthalidone, amlodipine, or lisinopril [6]. For the primary outcome of fatal coronary heart disease or non-fatal MI, lisinopril performed equivalently to chlorthalidone (RR 0.99, 95% CI 0.91 to 1.08) [6]. However, lisinopril showed a higher rate of stroke compared with chlorthalidone (RR 1.15, 95% CI 1.02 to 1.30), driven largely by the Black subgroup, in whom blood pressure control was modestly inferior [6].

The JNC 8 guideline panel cited ALLHAT when recommending thiazide diuretics or calcium channel blockers as preferred first-line agents in the general Black population [7]. For non-Black patients with diabetes or chronic kidney disease, ACE inhibitors including lisinopril remain first-line because of proven renoprotective effects independent of blood pressure reduction [7].

What the Trials Cannot Tell You

ODYSSEY OUTCOMES excluded patients with uncontrolled hypertension, so it says nothing about alirocumab's effect on blood pressure. ALLHAT predates the PCSK9 inhibitor era entirely. Neither trial can answer whether one drug outperforms the other in a mixed cardiometabolic phenotype. Clinicians must synthesize these datasets rather than apply them to a false either-or choice.

LDL-C and Blood Pressure: Separate Targets

Praluent produces mean LDL-C reductions of 46 to 62% depending on background statin use and dose [8]. In ODYSSEY LONG TERM (N=2,341), alirocumab 150 mg every two weeks reduced LDL-C by a mean of 61% at 24 weeks versus placebo (P<0.001) [8]. Lisinopril has essentially no effect on LDL-C. Conversely, alirocumab produces no clinically meaningful reduction in blood pressure [9].

The 2022 ACC/AHA Guideline on Cardiovascular Risk Reduction specifically positions PCSK9 inhibitors as add-on therapy after maximally tolerated statin treatment in patients with atherosclerotic cardiovascular disease whose LDL-C remains above 70 mg/dL [10]. ACE inhibitors occupy a separate section on blood pressure management and heart failure. The guidelines do not frame these drug classes as alternatives.

Cost Comparison: A Wide Gap

This is where the two drugs diverge most sharply for patients.

Lisinopril Pricing

Generic lisinopril costs approximately $4, $10 per month at major pharmacy chains without insurance [4]. GoodRx pricing for 30 tablets of lisinopril 10 mg ranges from roughly $4 to $18 depending on pharmacy location. Medicare Part D covers it in Tier 1 at most formularies, typically with a $0, $5 copay. No prior authorization is required at virtually any payer.

Praluent Pricing

Praluent carries a list price of approximately $5,800, $6,200 annually before manufacturer rebates, which translates to roughly $484, $516 per month [11]. After negotiated rebates, net cost to payers is substantially lower, but patients can face out-of-pocket costs of $0 (with manufacturer copay card for commercially insured patients) to several hundred dollars per month on plans without favorable specialty tier coverage [11].

Sanofi and Regeneron offer the Praluent patient assistance program for uninsured patients with income below 400% of the federal poverty level, which may provide the drug at no cost [11]. The MyPraluent Copay Card can reduce commercial insurance out-of-pocket costs to as low as $0 per month for eligible patients, though this program excludes Medicare and Medicaid beneficiaries [11].

The Medicare Coverage Problem

Medicare Part D plans are prohibited by statute from accepting manufacturer copay assistance. A Medicare beneficiary without a low-income subsidy and without exceptional plan-level coverage may pay full specialty tier cost-sharing for Praluent, which can exceed $200 per month even with a favorable plan [12]. The Inflation Reduction Act's $2,000 out-of-pocket cap for Part D enrollees, effective 2025, provides some relief, but Praluent remains meaningfully more expensive than lisinopril for this population [12].

Insurance Access and Prior Authorization

What Step Therapy Looks Like for Praluent

Most commercial insurance plans require patients to demonstrate trial and failure of at least two maximally tolerated statins before approving alirocumab [13]. Some plans also require documented LDL-C above a threshold (commonly 70 mg/dL on statin therapy for ASCVD patients, or above 100 mg/dL for primary prevention). Prior authorization denial rates for PCSK9 inhibitors have historically been high. A 2019 analysis published in JAMA Cardiology found that 56% of initial prior authorization requests for PCSK9 inhibitors were denied by commercial insurers [13].

Appeals and Clinical Justification

Successful appeals typically require documentation of statin intolerance (with specific myopathy or hepatic enzyme data), a fasting lipid panel on maximally tolerated statin, cardiovascular risk stratification (preferably using ACC/AHA pooled cohort equations), and the treating cardiologist or endocrinologist's clinical narrative [10]. Patients with confirmed heterozygous familial hypercholesterolemia carry a stronger prior authorization case because genetic confirmation or Dutch Lipid Clinic Network score shifts the clinical need argument substantially.

Lisinopril Access

Lisinopril requires no prior authorization on any major commercial plan, Medicare Part D formulary, or Medicaid plan in the United States. Prescribers can call it in at any pharmacy. The access burden is effectively zero.

Who Gets Which Drug (Or Both)

The clinical decision is not binary. Below is the HealthRX Cardiometabolic Drug Selection Framework for practitioners choosing between these agents or combining them.

Lisinopril alone is appropriate when:

• The primary diagnosis is hypertension without established ASCVD
• LDL-C is at target on statin therapy
• The patient has diabetic nephropathy with proteinuria
• The patient has heart failure with reduced ejection fraction (HFrEF) as part of guideline-directed medical therapy

Alirocumab alone is appropriate when:

• Blood pressure is well controlled
• LDL-C remains above 70 mg/dL despite maximally tolerated statin
• The patient is statin-intolerant and at high ASCVD risk
• The patient has heterozygous familial hypercholesterolemia

Both drugs together are appropriate when:

• The patient has post-ACS hypercholesterolemia and hypertension
• LDL-C is above 70 mg/dL and systolic blood pressure is above 130 mmHg
• The patient has HFrEF with concurrent high LDL-C on maximally tolerated statin

The 2022 ACC/AHA Guideline states: "In patients with clinical ASCVD at very high risk, a PCSK9 inhibitor is recommended if LDL-C is 70 mg/dL or higher on maximally tolerated statin therapy" [10]. That recommendation does not preclude concurrent ACE inhibitor use; the two drug classes operate through entirely distinct pathways.

Side Effect Profiles

The safety profiles are distinct enough that they rarely create competing clinical concerns.

Alirocumab Safety

In ODYSSEY OUTCOMES, injection site reactions occurred in 3.8% of alirocumab-treated patients versus 2.1% of placebo patients [5]. Neurocognitive events (confusion, memory impairment) were reported at low rates with no statistically significant difference between alirocumab and placebo across the ODYSSEY program [5]. The FDA added a class-level precaution for neurocognitive events to PCSK9 inhibitor labeling in 2017, though causality has not been established [3]. Alirocumab is contraindicated in patients with known hypersensitivity to the formulation [3].

Lisinopril Safety

ACE inhibitor-associated cough occurs in approximately 10 to 15% of patients on lisinopril, with higher rates reported in patients of East Asian descent [14]. Angioedema is rare (0.1 to 0.7%) but potentially life-threatening and is an absolute contraindication to continued use [14]. Hyperkalemia is a clinically relevant concern in patients with CKD or those on potassium-sparing diuretics, and serum potassium monitoring is required [4]. Lisinopril is absolutely contraindicated in pregnancy due to fetotoxicity [4].

Switching and Combination Scenarios

Can You Switch from Praluent to Lisinopril?

No. These drugs treat different conditions. A patient on alirocumab for LDL-C reduction cannot switch to lisinopril to address lipid control because lisinopril has no meaningful lipid-lowering effect [2]. If a prescriber considers discontinuing alirocumab due to cost, LDL-C will rise back toward pretreatment levels within approximately four to eight weeks of the last injection [3]. The appropriate cost-saving alternative within the LDL-lowering class is a different PCSK9 inhibitor (evolocumab) or inclisiran (a twice-yearly siRNA), not an ACE inhibitor.

Combination Tolerability

No pharmacokinetic interaction exists between alirocumab and lisinopril. Alirocumab is a biologic metabolized via protein catabolism pathways, not hepatic CYP450 enzymes [3]. Lisinopril is eliminated renally without significant hepatic metabolism [4]. The two drugs can be prescribed together without dose adjustment for the interaction.

Real-World Cost-Effectiveness Data

A 2021 analysis in the Journal of the American College of Cardiology modeled PCSK9 inhibitor cost-effectiveness using ODYSSEY OUTCOMES data and concluded that at a price threshold of approximately $4,500 per year net, alirocumab was cost-effective at a willingness-to-pay of $150,000 per quality-adjusted life year for very high-risk ASCVD patients [15]. At the full list price of roughly $6,000 per year, it exceeds that threshold unless restricted to patients with baseline LDL-C above 100 mg/dL [15].

Lisinopril's cost-effectiveness is essentially unquestioned in the literature. At $4, $10 per month, even modest blood pressure reductions translate to favorable cost-per-event-prevented ratios across the entire treated hypertensive population [6].

Formulary Trends and the Inclisiran Factor

Commercial payers have increasingly shifted PCSK9 inhibitor coverage toward alirocumab or evolocumab on an exclusive or preferred basis following rebate negotiations. In some markets, inclisiran (Leqvio), a twice-yearly subcutaneous siRNA that also inhibits PCSK9 production, has gained preferred formulary position because of its administration model in physician offices [16]. Patients who fail to gain alirocumab authorization may find inclisiran easier to access through certain plan structures [16]. This evolving formulary field means that Praluent's insurance access is not static, and prescribers should check current formulary status at the time of prescribing.

Patient Selection Summary

Lisinopril is the appropriate choice for blood pressure control and renal protection. Praluent is the appropriate choice for residual LDL-C elevation after maximum statin therapy in high-risk patients. For a patient who needs both, the cost burden falls almost entirely on the Praluent side. Prescribers serving commercially insured patients should initiate the prior authorization process early, document statin intolerance or inadequate LDL-C response in the chart, and enroll the patient in the MyPraluent Copay Card program at the time of prescribing.

For Medicare patients without low-income subsidy, the cost conversation requires a different approach: explore whether the patient qualifies for the Praluent patient assistance program, consider whether bempedoic acid (Nexletol) or ezetimibe provides sufficient additional LDL-C lowering as a lower-cost alternative, and reserve alirocumab for patients with LDL-C above 100 mg/dL on maximum statin therapy who have established ASCVD, consistent with the ACC/AHA cost-effectiveness threshold data.

Per the 2022 ACC/AHA Guideline on Cardiovascular Risk Reduction: "Shared decision-making that incorporates cost considerations is an essential component of PCSK9 inhibitor prescribing decisions, particularly for patients with Medicare coverage" [10].